Shalby Ltd

Stage 4 · Declining · week 15

As of 20 Nov 2026, Shalby is in Stage 4, the downtrend phase, now in week 15 (since 10 Aug 2026). It closed at ₹122, 45.7% below its 52-week high and below its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. More about the company

₹122.2
Close, 20 Nov 2026
+0.21% on the day
₹1,313 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dHospitals & Diagnostic Centres 18.8%-3.1 pts

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

RS rank

Edge

—

SHALBY is in a decline, 20% below its 200-day average. Declining stocks have lagged the market more than any other group; we wait for a base before looking again.

Its relative strength is 9 of 99, below the middle among NSE stocks over the past year. Hospitals & Diagnostic Centres ranks 15 of 106 industries by the strength of its stocks, among the leaders.

Is SHALBY early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 27w
S4 47w
S4 18w
S4 15w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 27w → S3 10w → S4 4w → S1 13w → S4 47w → S1 7w → S2 11w → S3 6w → S4 18w → S1 11w → S4 15w current
Total tracked: 169 weeks across 11 stage runs.

SHALBY among Hospitals & Diagnostic Centres24th of 32 by relative strength

All 32 →
Stocks in Hospitals & Diagnostic Centres ranked by relative strength, with stage and one-month change
#StockStageRS1M
1KMCSHILStage 2 · wk 5498+35.8%
2VIJAYAStage 3 · wk 290+16.2%
3YATHARTHStage 2 · wk 2789+18.6%
4LALPATHLABStage 2 · wk 2383+9.3%
5APOLLOHOSPStage 3 · wk 782+21.1%
6MEDANTAStage 3 · wk 581+20.1%
7KIMSStage 4 · wk 178+18.0%
8METROPOLISStage 3 · wk 677+6.1%
…24SHALBYStage 4 · wk 159+1.3%
vs 52W High
-45.7%
₹113.4 lo₹224.8 hi
45.7% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 15
1w13w26w
Week 15, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-20.1%
200 DMA: ₹152.9 · sloping down
The stock is below its 200-day average, the mark of a downtrend. Stage analysis waits for the price to reclaim that line.
Rel Volume
0.95x
vs 50-day avg
Volume was close to average, nothing unusual. In Stage 4, heavy volume on down days confirms selling, and low-volume bounces are common.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+1.3%
3M
-21.4%
6M
-26.7%
YTD
-40.1%
1Y
-47.0%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
18.8%
20d Δ
-3.1pp
1M return
+17.6%
3M return
+0.9%
Industry Stage-2 % · last 20 days
Industry has 5 Stage 2 leaders. See Hospitals & Diagnostic Centres Stage 2 →

Mutual fund holdings

Held by 5 mutual funds in portfolios to October 2026: 0 active funds and 5 index funds and ETFs.

In October, no active fund changed its holding.

All 5 funds and what each did in October

Mutual funds holding SHALBY: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 18 Sep 2025
Recent Stage Timeline
2026-11-20S4
Wk 15 · Vol 0.95x
2026-11-19S4
Wk 14 · Vol 0.65x
2026-11-18S4
Wk 14 · Vol 0.90x
2026-11-17S4
Wk 14 · Vol 0.69x
2026-11-16S4
Wk 14 · Vol 2.28x
2026-11-13S4
Wk 14 · Vol 1.25x
2026-11-12S4
Wk 13 · Vol 0.59x
2026-11-11S4
Wk 13 · Vol 1.15x
2026-11-09S4
Wk 13 · Vol 1.19x
2026-11-06S4
Wk 13 · Vol 1.08x
2026-11-05S4
Wk 13 · Vol 1.22x
2026-11-04S4
Wk 12 · Vol 1.62x
Moving averages & range
50 DMA
₹130.4
200 DMA
₹152.9
52W High
₹224.8
52W Low
₹113.4
5D Low
₹119
Resistance levels (recent highs)
20d High
₹127.4
60d High
₹156.9
120d High
₹176.8
250d High
₹223.9
Next resistance
+4.3%
to 20d High
P/E (TTM)
34.9
Forward 13.2
Earnings Growth (YoY)
+38.0%
Revenue +9.7%
ROE
+3.8%
Profit margin +3.3%
Dividend Yield
0.00%
P/B 1.4

Shalby: quick answers

What stage is Shalby in?

As of 20 Nov 2026, Shalby (SHALBY) is in Stage 4, the downtrend phase. It entered Stage 4 on 10 Aug 2026 and is in week 15. What the four stages mean

Is Shalby in an uptrend?

No. Shalby is in a Stage 4 downtrend. It trades 20.1% below its 200-day average, which is falling.

How far is Shalby from its 52-week high?

Shalby closed at ₹122 on 20 Nov 2026, 45.7% below its 52-week high of ₹225. Its 52-week low is ₹113.

How has Shalby performed over the past year?

As of 20 Nov 2026, Shalby is down 47.0% over the past year and down 40.1% so far in 2026.

Which sector and industry is Shalby in?

Shalby is in the Hospitals & Diagnostic Centres industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Hospitals & Diagnostic Centres

About this companyHealth Care· Hospitals & Diagnostic Centres

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; and interventional and diagnostic radiology. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.